COMMUNIQUÉS West-GlobeNewswire

Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
13/08/2026
Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026 FOSTER CITY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: [...]
Profusa Announces 1-for-4 Reverse Stock Split
13/08/2026
BERKELEY, California, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the [...]
Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update
13/08/2026
Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 PMA supplement for second-generation LungFit PH system under FDA review; [...]
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
13/08/2026
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a biotechnology company dedicated to immunotherapy research, today announced financial results for [...]
American Shared Hospital Services Reports Second Quarter and First Half 2026 Financial Results
13/08/2026
Second Quarter Revenue Increased 19% to $8.4 Million Driven by Strong Growth from Direct Patient Services Operating Cash Flow Reached $4.4 Million in First Half of 2026 Conference Call Scheduled for Today at 1:00 PM ET [...]
6 Stress Points That Break Retail Customer Service During Peak Season
13/08/2026
The Retail and Ecommerce Peak Resilience Index from Transcom, with a free eight-question stress test, is now available and classifies operations as fragile, reactive, elastic, or adaptive. Six volatility stress points [...]
LENSAR® Reports Second Quarter 2026 Results and Provides Business Update
13/08/2026
10 ALLY Robotic Cataract Laser Systems ® (“ALLY System”) Placements in Second Quarter 2026; Backlog of 13 ALLY Systems as of June 30, 2026 Second Quarter Recurring Revenue was $13.7 million Total Laser Installed Base [...]
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
13/08/2026
Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of patients treated at or below a dose cap Updated data from the MICVO [...]
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
13/08/2026
- Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027 - - New study data confirm bioequivalence of obexelimab single-dose prefilled autoinjector pen compared [...]
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
13/08/2026
EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract for NexoBrid ® Second [...]
Photys Therapeutics and Polymed Biopharmaceuticals Announce the Initiation of a Phase I Clinical Trial of PHT-776/HPB-143, an Oral IRAK4 PROTAC Degrader
13/08/2026
WALTHAM, Mass. and HANGZHOU, China, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Photys Therapeutics, Inc. (“Photys”), a proximity-based therapeutics company, and Polymed Biopharmaceuticals, Inc. (“Polymed”), a global biotech [...]
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
13/08/2026
SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
13/08/2026
Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and [...]
Valneva publie ses résultats financiers du premier semestre 2026 et fait un point sur ses activités
13/08/2026
Ventes totales de produits de 64,0 millions d’euros o En ligne avec les attentes ; confirmation de la prévision annuelle de ventes comprises entre 135 et 150 millions d’euros. Solide position de trésorerie de 121,5 [...]
Zealand Pharma Announces Financial Results for the First Half of 2026
13/08/2026
Company announcement – No. 39 / 2026 Zealand Pharma Announces Financial Results for the First Half of 2026 A landmark first half defined by key milestones delivered for leading obesity assets, and a continued momentum [...]
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
13/08/2026
Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan [...]
Kuros Biosciences delivers 45% H1 2026 year-over-year sales growth and increases overall profitability
13/08/2026
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences delivers 45% H1 2026 year-over-year sales growth and increases overall profitability Schlieren (Zurich), Switzerland, August 13, 2026 [...]
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
13/08/2026
ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab- [...]
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
13/08/2026
U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) with Priority Review for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); Prescription Drug User Fee Act (PDUFA) target [...]

Pages